Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Jay Galeota
|
| gptkbp:focusesOn |
neuroscience
therapeutics gut-brain axis |
| gptkbp:foundedIn |
2015
|
| gptkbp:founder |
gptkb:Richard_Axel
gptkb:Tom_Maniatis gptkb:Charles_Zuker |
| gptkbp:fundedBy |
over $250 million
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kallyope
|
| gptkbp:investor |
gptkb:Polaris_Partners
gptkb:Lux_Capital gptkb:The_Column_Group gptkb:Two_Sigma_Ventures Illumina Ventures |
| gptkbp:studiedBy |
metabolic diseases
CNS disorders gut-brain signaling |
| gptkbp:website |
https://www.kallyope.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
|
| gptkbp:bfsLayer |
7
|